Details:
F351 was generally well tolerated in this study. In patients treated with placebos, 60 mg/tid F351, 90 mg/tid F351, and 120 mg/tid F351, respectively.
Lead Product(s): Hydronidone,Entecavir
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020